T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
- 12 August 2011
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 26 (2), 365-367
- https://doi.org/10.1038/leu.2011.205
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsPublished by The American Association of Immunologists ,2011
- Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin LymphomaJournal of Immunotherapy, 2009
- Human CD38: a (r)evolutionary story of enzymes and receptorsLeukemia Research, 2000
- Therapy of human B‐cell lymphoma bearing scid mice is more effective with anti‐CD19‐and anti‐CD38‐saporin immunotoxins used in combination than with either immunotoxin used aloneInternational Journal of Cancer, 1995
- Evaluation of CD38 as target for immunotherapy in multiple myeloma [letter; comment]Blood, 1995
- Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma [see comments]Blood, 1994